Evidence map›Paper›PMID 40606550›Full record

ReviewJournal of toxicologic pathology2025

Report of the AI Pathology Task Force, Non-clinical Evaluation Expert Committee, Japan Pharmaceutical Manufacturers Association: an overview of recent publications about AI pathology.

Emi Tomikawa, Satoshi Sakai, Yoshinori Yamagiwa, Yumi Kangawa, Yusuke Kagawa, Yuki Kato, Kensuke Kojima, Akira Inomata, Izumi Matsumoto, Gen Sato and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of toxicologic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Emi TomikawaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Satoshi SakaiAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Yoshinori YamagiwaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Yumi KangawaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Yusuke KagawaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Yuki KatoAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Kensuke KojimaAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Akira InomataAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Izumi MatsumotoAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Gen SatoAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Mutsumi SuzukiAI Pathology Task Force, Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of artificial intelligence (AI) in non-clinical pathology is rapidly expanding. In this study, we conducted a literature survey of articles published after 2017 that used AI to analyze the histopathological images of experimental animals. We identified 44 articles that used AI for various purposes, including the detection of abnormal sites, determination and quantification of normal tissues, and classification of normal/abnormal images. AI systems or applications were either custom-built, commercially available, or a combination of both. Rats and mice were mainly used, and the liver was the most frequently analyzed organ. Our findings suggest that AI can be useful in non-clinical pathology and that collaboration between pharmaceutical companies or cooperation with IT experts can be a potential approach to further advance the utilization of AI in this field.

Indexed as

artificial intelligencedigital pathologyexperimental animalsimage analysisliterature surveynon-clinical

Identifiers

PMID40606550
PMCPMC12208865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.